Journal of Gastroenterology and Hepatology最新文献

{"title":"Depression or Anxiety in GI Outpatients: Upper GI Symptoms and Symptom Clusters Showed Stronger Associations Than Lower GI.","authors":"Zhiyue Xu, Shengyan Zhang, Saier Li, Shu Xu, Dongke Wang, Siran Zhu, Xinghuang Liu, Jun Song, Jingsong Liu, Xiaohua Hou, Tao Bai, Likun Zhong","doi":"10.1111/jgh.16955","DOIUrl":"https://doi.org/10.1111/jgh.16955","url":null,"abstract":"<p><strong>Background and aim: </strong>Gastrointestinal (GI) problems have been always linked to psychiatric disorders. The aim of our study was to explore specific GI symptoms or symptom clusters that may indicate the presence of depression or anxiety in outpatients.</p><p><strong>Methods: </strong>One thousand one hundred twenty-five outpatients from 20 hospitals completed questionnaires assessing GI symptoms, depression (the Patient Health Questionnaire-9, PHQ-9), and anxiety (General Anxiety Disorder-7, GAD-7). Principal component analysis was employed to identify symptom clusters based on 22 GI symptoms. The patients were categorized into three groups: Control (PHQ-9 < 5 and GAD-7 < 5), DA1 (5 ≤ PHQ-9 < 10 or/and 5 ≤ GAD-7 < 10), and DA2 (PHQ-9 ≥ 10 or GAD-7 ≥ 10).</p><p><strong>Results: </strong>There were 781, 249, and 95 patients in the group of Control, DA1, and DA2, respectively. Fecal incontinence (4.835, [2.213-10.563]), heartburn (3.338, [2.416-4.611]), belching (2.862, [2.145-3.821]), and globus sensation (2.845, [2.110-3.837]) demonstrated the highest potential risk of psychiatric comorbidity. The 22 GI symptoms were categorized into eight clusters. Dyspepsia-related Cluster F2, reflux-related Cluster F3, and esophageal-related Cluster F4 were noteworthy in the identification of psychiatric comorbidity. Cluster F4, including globus sensation, discomfort with swallowing, and chest pain, exhibited the most significant increase in the prevalence of depression or anxiety (2.645, [1.851-3.778]).</p><p><strong>Conclusion: </strong>Specific GI symptoms including heartburn, belching, globus sensation, and GI symptom clusters including F2, F3, and F4 were noteworthy in the identification of psychiatric comorbidity. They were mostly focused on the upper GI tract. It is critical for gastroenterologists to recognize psychiatric comorbidities and implement appropriate measures accordingly.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Ultrasound-Guided Gastrojejunostomy as a Primary Treatment Modality for Malignant Gastric Outlet Obstruction: A Large Multicenter Experience.","authors":"Nikhil Sonthalia, Radhika Chavan, Pankaj Singh, Jimmy Narayan, Sukrit Sud, Chirag N Shah, Shankar Zanwar, Awanish Tewari, Sanjay Rajput, Vikas Singla, Akash Roy, Shanky Koul, Akash Goel, Uday C Ghoshal, Mahesh Kumar Goenka","doi":"10.1111/jgh.16959","DOIUrl":"https://doi.org/10.1111/jgh.16959","url":null,"abstract":"<p><strong>Objectives: </strong>This work aims to describe technical feasibility and clinical outcomes of endoscopic-ultrasound-guided gastrojejunostomy (EUS-GJ) as a first line treatment option for malignant gastric outlet obstruction (mGOO).</p><p><strong>Methods: </strong>This is a large multicenter study where patients undergoing EUS-GJ across seven tertiary care centers from India were analyzed. The primary outcomes were technical success defined as correct stent placement without any leak, and clinical success defined as improvement in gastric outlet obstruction symptom score (GOOSS) on follow-up. Secondary outcomes were (a) adverse events rates, (b) symptoms recurrence, (c) death on follow-up, and (d) resumption of chemotherapy.</p><p><strong>Results: </strong>A total of 71 patients underwent EUS-GJ with technical success of 94.3%. After successful stent placement, all patients tolerated oral liquid diet on day 1, whereas 89.5% and 95.5% tolerated oral solid diet on day 2 and day 7, respectively. Overall, 9/71(12.6%) patients had major adverse events, which included maldeployment in 6/71(8.4%). Mean duration of follow-up was 76.13 ± 58.09 days. On follow-up, reintervention was required in two (3%) patients. Around two-thirds of patients gained weight and could resume their chemotherapy post-EUS-GJ. Kaplan-Meier survival analysis showed that post EUS-GJ, mean overall survival (symptom recurrence or death) of 144.39 ± 11.53 days (95% CI 121.7-167.0).</p><p><strong>Conclusion: </strong>EUS-GJ is an excellent modality for the palliation of mGOO, providing high clinical success with extremely low rates of reintervention and acceptable safety profile. It should be considered as a primary modality for managing these patients, and enteral stent should be reserved for patients where EUS-GJ is not possible.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bifidobacterium Lactobacillus Triple Viable Alleviates Slow Transit Constipation by Regulating Gut Microbiota and Metabolism.","authors":"Mei Luo, Peiwei Xie, Xuehong Deng, Jiahui Fan, Lishou Xiong","doi":"10.1111/jgh.16960","DOIUrl":"https://doi.org/10.1111/jgh.16960","url":null,"abstract":"<p><strong>Background: </strong>Gut microbiota plays a crucial role in the pathogenesis and treatment of functional constipation (FC). The aim of this study was to explore the therapeutic effects of Bifidobacterium Lactobacillus triple viable on slow transit constipation (STC).</p><p><strong>Methods: </strong>Patients with STC who met the Rome IV criteria received Bifidobacterium Lactobacillus triple viable. Gastrointestinal transit time (GITT) and constipation-related symptoms were assessed before and after receiving Bifidobacterium Lactobacillus triple viable. Additionally, a rat STC model was induced by loperamide and was treated with Bifidobacterium Lactobacillus triple viable to evaluate whether Bifidobacterium Lactobacillus triple viable could improve constipation in the rats and to explore the possible mechanisms involved.</p><p><strong>Results: </strong>In patients with STC, Bifidobacterium Lactobacillus triple viable accelerated GITT and improved constipation-related symptoms, including bowel movement frequency, hard bowel movement, incomplete defecation, defecation time, purgative measures, and stool form. In addition, Bifidobacterium Lactobacillus triple viable improved body weight, food intake, bowel movement, the fecal water content, and the intestinal propulsion rate in STC rats. It regulates the gut microbiota structure in rats; increases serum acetylcholine (Ach), 5-hydroxytryptamine (5-HT), substance P (SP), and vasoactive intestinal peptide (VIP); increases fecal long-chain fatty acids (LCFAs); upregulates the mRNA expression of aquaporin 3 (AQP3) and aquaporin 3 (AQP8); and downregulates the mRNA expression of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), and interleukin-1β (IL-1β).</p><p><strong>Conclusions: </strong>Bifidobacterium Lactobacillus triple viable ameliorated the GITT and constipation-related symptoms of patients with STC and improved the STC in rats by regulating the gut microbiota and metabolism.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Visibility and Performance of Small Bowel Video Capsule Endoscopy With and Without Pre-Procedural Purge Preparation in the Same Patients.","authors":"Margalit Yehuda Reuma, Davidov Yana, Selinger Limor, Ungar Bella, Lahat Adi, Yablecovitch Doron, Neuman Sandra, Kopylov Uri, Ben Horin Shomron, Eliakim Rami","doi":"10.1111/jgh.16954","DOIUrl":"https://doi.org/10.1111/jgh.16954","url":null,"abstract":"<p><strong>Background: </strong>Small bowel (SB) video capsule endoscopy (VCE) is an established diagnostic tool for the investigation of SB pathologies. Despite clinical studies and a few meta-analyses, an area of continuing controversy is the role of pre-procedural bowel preparation.</p><p><strong>Objectives: </strong>We compared the visibility and performance of VCE with and without purge preparation in the same patients.</p><p><strong>Design: </strong>Post hoc analysis of randomized control trial.</p><p><strong>Methods: </strong>This is a post hoc analysis of the prospective randomized CURE-CD Trial (Comprehensive individUalized pRoactive ThErapy of Crohn's Disease trial). Established Crohn's disease (CD) patients in clinical remission were enrolled and classified into two groups according to relapse risk assessment. All patients are followed up in our clinic and undergo laboratory tests every 3 months and serial VCE studies every 6 months. The first VCE is done after bowel preparation with a clear liquid diet, PEG, and laxative, whereas the subsequent VCEs, when disease is confined to SB only, are done after a day on clear liquid diet. The VCE visibility is rated (1-4 points) by a blind observer, unaware to the preparation regimen.</p><p><strong>Results: </strong>Forty patients who underwent at least two VCEs, at baseline and after 6 months were included. Visibility scores were similar in these two time points (3.15 vs. 3.10, p = 0.8). Among the low-risk patients' group (n = 16) in whom the clinical parameters (CDAI, CRP, and fecal calprotectin) have not changed significantly during this period, Inflammatory scores assessed by the capsule Lewis score (LS) and PillCam-CD score (PCDS) were similar (median LS 225 vs. 225, p = 0.87, median PCDS 4 vs. 2, p = 0.37).</p><p><strong>Conclusion: </strong>The visibility and performance of SB VCE for monitoring Crohn's disease is not significantly influenced by purge preparation.</p><p><strong>Trial registration: </strong>Clinicatrials.gov identifier: NCT03555058.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Irisin Alleviates Impaired Mitochondrial Fusion via Enhancing PKA/SIRT3/mTOR Pathway in Hepatic Steatosis.","authors":"Jia Li, Ying Zhao, Zhihong Wang, Anran Ma, Yunzhi Ni, Di Wu, Yue Zhou, Na Zhang, Li Zhang, Yongsheng Chang, Qinghua Wang","doi":"10.1111/jgh.16950","DOIUrl":"https://doi.org/10.1111/jgh.16950","url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatic steatosis, a hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD), arises from disrupted lipid homeostasis. Mitochondrial dysfunction, particularly imbalances in mitochondrial fusion and fission, plays a crucial role in MASLD progression. Irisin, an exercise-induced myokine, is involved in lipid metabolism, though its precise mechanisms of action remain unclear.</p><p><strong>Methods: </strong>An irisin-Fc fusion protein was prophylactically administered to mice with high-fat diet (HFD)-induced MASLD for 12 weeks. Liver tissues were analyzed using oil red O staining and hepatic and serum lipid profiling to evaluate irisin's therapeutic efficacy. Expression levels of proteins involved in fatty acid metabolism and mitochondrial dynamics were assessed. In palmitate (PA)-treated HepG2 cells, mitochondrial morphology was analyzed, and fatty acid uptake was determined through colocalization of fluorescently labeled PA with mitochondria. PKA activity and SIRT3 expression were validated using a PKA agonist/inhibitor and SIRT3 overexpression or knockdown via plasmid transfection and siRNA.</p><p><strong>Results: </strong>Irisin significantly reduced lipid accumulation in HFD-induced MASLD mouse models and PA-treated HepG2 cells. These effects were associated with enhanced mitochondrial fusion, indicated by increased expression of mitofusin 2 and optic atrophy type 1 and reduced excessive fission, evidenced by decreased activation of dynamin-related protein 1. These changes were mediated partly through PKA/SIRT3/mTOR pathway activation, which facilitated mitochondrial fatty acid uptake and β-oxidation while inhibiting lipogenesis.</p><p><strong>Conclusions: </strong>Our results demonstrate the protective role of irisin in alleviating hepatic steatosis by regulating mitochondrial dynamics. These findings provide valuable evidence of the antisteatogenic mechanisms of irisin and its therapeutic potential for MASLD management.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Impact of Disorders of Gut-Brain Interaction in Multiethnic Malaysia: An In-Depth Analysis of Local Data From the Rome Foundation Global Epidemiology Study.","authors":"Daniel Martin Simadibrata, Elvira Lesmana, Thai Hau Koo, Hematram Yadav, Kuck Meng Chong, Kamarul Imran Musa, Kueh Yee Cheng, Nashrullhaq Tagiling, NorFilza M Mokhtar, NurHazwani Abdul Hamid, Nurzulaikha Abdullah, Mohd Helmy Mokhtar, Norhazlina Abdul Wahab, Pojsakorn Danpanichkul, Yung Yang Chong, Zhiqin Wong, Ami Sperber, Shrikant I Bangdiwala, Olafur S Palsson, Yeong Yeh Lee","doi":"10.1111/jgh.16953","DOIUrl":"https://doi.org/10.1111/jgh.16953","url":null,"abstract":"<p><strong>Introduction: </strong>Previous epidemiology studies from Malaysia on disorders of gut-brain interaction (DGBI) have utilized variable criteria. Furthermore, the impact of DGBI on quality of life (QoL), healthcare utilization, diet, work productivity, and sleep in a multiethnic Asian setting like Malaysia remains underexplored. Here, we aimed to determine the epidemiology and impact of DGBI among multiethnic Malaysians based on the Rome IV criteria.</p><p><strong>Methods: </strong>2072 Malaysian participants from the Rome Foundation Global Epidemiology Study (RFGES) with complete data on DGBI were included in the in-depth analysis. We assessed the prevalence of DGBI diagnoses, psychological distress, QoL, healthcare utilization, dietary patterns, impact on sleep, work productivity, and activity impairment.</p><p><strong>Results: </strong>The overall prevalence of any DGBI in Malaysia was 19.3% (95% CI 17.6%-21.0%). The top three most prevalent DGBI diagnoses were functional constipation (5.1%; 95% CI 4.2%-6.1%), functional dyspepsia (3.4%; 95% CI 2.7%-4.3%), and functional diarrhea (1.6%; 95% CI 1.1%-2.2%). Participants with DGBI reported higher levels of psychological distress (somatization, anxiety, and depression), significantly higher healthcare utilization, and dietary change (low FODMAPs but higher Mediterranean-based diet and probiotics). Furthermore, there was greater daytime sleepiness and higher proportions of presenteeism, overall work impairment, and activity impairment in individuals with DGBI.</p><p><strong>Conclusion: </strong>The disease burden of DGBI is significant in Malaysia, with increased psychological distress, healthcare utilization, dietary change, greater daytime sleepiness, and greater overall work and activity impairment.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Helicobacter pylori Infection and Antibiotic Resistance via String Test Coupled With qPCR Method: A Comparative Methodological Study.","authors":"Yu-Ting Si, Xue-Song Xiong, Shen-Ke Zhang, Jin-Xin Lai, Yu-Ting Li, Zeeshan Umar, Luan Luan, Jia-Wei Tang, Zheng-Kang Li, Fen Li, Bing Gu, Liang Wang","doi":"10.1111/jgh.16962","DOIUrl":"https://doi.org/10.1111/jgh.16962","url":null,"abstract":"<p><strong>Background and aim: </strong>Helicobacter pylori (H. pylori) infection has long been a significant global public health concern, with antibiotic resistance becoming increasingly severe. Gastric fluid qPCR detection can provide information on H. pylori infection and antibiotic resistance.</p><p><strong>Methods: </strong>This study compares a series of diagnostic methods among 300 participants to reveal best practices for detecting H. pylori infection and/or profiling antibiotic resistance, including urea breath test (UBT), rapid urease test (RUT), gastric mucosa qPCR (GM-qPCR), and the novel gastric fluid qPCR (GF-qPCR).</p><p><strong>Results: </strong>The infection rates detected by UBT and RUT were 32.33% and 23.33%, respectively. Through qPCR analysis, the infection rates in gastric fluid and gastric mucosal were 27.67% and 25.33%. When comparing three methods of detecting H. pylori using the UBT as the reference standard, it was found that the sensitivity, specificity, positive and negative predictive values, and accuracy of gastric fluid qPCR performed the best. The consistency of the four methods was assessed using the Kappa value, which yielded a value of 0.792. Additionally, 45 individuals showed inconsistent results. When using qPCR to detect antibiotic resistance in gastric fluid and gastric mucosal samples, we observed resistance rates of 42.17% (35/83) for clarithromycin and 49.40% (41/83) for levofloxacin in gastric fluid samples. In contrast, resistance rates in gastric mucosal tissue samples were significantly lower at 16.87% (14/76) for clarithromycin and 22.37% (17/76) for levofloxacin.</p><p><strong>Conclusions: </strong>The GF-qPCR method is a promising technique for detecting H. pylori infection and antibiotic resistance, with the potential for providing guided treatment plans.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Trial: The Optimal Timing of the Endoscope Insertion After Oral Lidocaine Spray. A Randomized Controlled Trial.","authors":"Hsueh-Chien Chiang, Chien-Ming Chiang, Wei-Lun Chang, Meng-Ying Lin","doi":"10.1111/jgh.16958","DOIUrl":"https://doi.org/10.1111/jgh.16958","url":null,"abstract":"<p><strong>Background and aim: </strong>Esophagogastroduodenoscopy (EGD) is a critical diagnostic tool for assessing upper gastrointestinal disorders, yet it can induce significant discomfort due to gag reflexes and pain. For patients with a higher risk for sedation, topical lidocaine spray at the hypopharynx is an alternative method. Yet, no standardized protocol exists regarding the optimal waiting period between administering lidocaine spray and commencing EGD. This study investigates the optimal waiting time between the application of topical lidocaine spray and the initiation of EGD to enhance patient comfort and procedural efficacy.</p><p><strong>Methods: </strong>Conducted as a single-center randomized controlled trial at our hospital, the research involved 160 patients who were divided into two groups based on waiting times of 1 or 3 min postlidocaine application. Both objective and subjective discomfort levels were evaluated during the procedure. Objective discomfort assessment included the elevation of heart rate and systolic blood pressure. Subjective discomfort assessment included throat pain, nausea sensation, and abdominal fullness recorded from the patient's questionnaire.</p><p><strong>Results: </strong>The study indicated that a 3-min wait significantly reduced objective measures of discomfort, such as heart rate and blood pressure elevations, and subjective discomfort ratings, including throat pain and nausea. Furthermore, patients in the 3-min group expressed a lower willingness to undergo future sedated endoscopies, highlighting the importance of minimizing sedation-related risks in high-risk populations.</p><p><strong>Conclusions: </strong>The study findings suggest that extending the waiting period after lidocaine administration improves patient outcomes during EGD, advocating for a standardized protocol of 3 min to optimize analgesia and procedural comfort.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT06497296.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021.","authors":"Xiangying Xie, Juan Su, Wei Wang, Huiling Wei, Qian Zhou, Ying Su, Lili Zhang","doi":"10.1111/jgh.16956","DOIUrl":"https://doi.org/10.1111/jgh.16956","url":null,"abstract":"<p><strong>Background and aim: </strong>To study the corresponding strategies to control stomach cancer, a comprehensive assessment of the disease burden is required. Herein, we present long-term trends in the burden of stomach cancer in China over the past three decades, as well as its epidemiological features.</p><p><strong>Methods: </strong>We characterized the burden of stomach cancer in China using the GBD 2021 methods and results, based on prevalence, incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) estimated using the DisMod-MR 2-1. We also used joinpoint and age-period-cohort (APC) analysis methods to interpret the epidemiological characteristics of stomach cancer, project the disease burden of stomach cancer in China over the next decade, and compare these trends with global prevalence patterns.</p><p><strong>Results: </strong>The age-standardized incidence (ASIR) and mortality rates (ASMR) in both sexes changed from 48.03 (40.21, 56.69) to 29.05 (22.42, 36.2) and from 46.05 (38.88, 54.43) to 21.51 (16.66, 26.61) per 100 000 people in China from 1990 to 2021. The age-standardized DALY rate in China decreased from 1181.61 (978.38, 1390.89) per 100 000 people in 1990 to 501.26 (387.29, 627.98) per 100 000 people in 2021. The average annual percentage change (AAPC) in age-standardized incidence, prevalence, and mortality rates for stomach cancer in China were -1.61 (95% CI: -1.73, -1.48), -0.50 (95% CI: -0.67, -0.32), and -2.44 (95% CI: -2.62, -2.26). The effects of age, period, and cohort on mortality rates differed.</p><p><strong>Conclusions: </strong>In the next decade, China's ASIR and ASMR for stomach cancer will continue to decline. However, despite the decrease in incidence, the overall burden of stomach cancer in China will remain significantly higher than the global average. The burden of stomach cancer in China will be a major public health challenge, given the country's large population base and aging population.</p>","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights on Weight Gain and MASLD Risk in Japanese Non-Obese Individuals.","authors":"Miya Li, Qinlin Zhang, Ruhong Zhou","doi":"10.1111/jgh.16951","DOIUrl":"https://doi.org/10.1111/jgh.16951","url":null,"abstract":"","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}